All In Biotech

Drug Trial Radar · NCT07616739

Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women

Evaluating the Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in ART-Naïve Pregnant Women

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Oct 15, 2028

Study completion Oct 15, 2028

Sponsor

Lead sponsor
Fundación HuéspedAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ViiV Healthcare
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Protocol Number: FH-94 Study Objetives: Primary: * To evaluate the virological response to Dolutegravir/Lamivudine in naive pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed neonates. Secondary: * To evaluate the incidence of maternal adverse events. * To evaluate perinatal outcomes at delivery. * To evaluate maximum virological suppression at delivery. * To evaluate the incidence of changes in body weight exceeding what is expected for gestation. * To evaluate the immune response based on changes in CD4, CD8, and CD4/CD8 ratio values during pregnancy. * Assess baseline resistance and the development of resistance to virological failure to integrase inhibitors and INTRs during treatment with DTG+3TC or DTG+TDF/XTC or DTG+TAF/FTC. * To evaluate the incidence of HIV infection in children that breastfeed. * To evaluate safety outcomes and virological response of DTG+3TC compared to DTG+TDF/XTC or DTG+TAF/FTC. Exploratory: * To explore the non-inferiority of DTG+3TC therapy compared to DTG+TDF/XTC or DTG+TAF/FTC treatment. * To evaluate the frequency of antiretroviral therapy withdrawal or modification before delivery.

Conditions

  • HIV-1-infection

Interventions

  • Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]Drug

    1 pill QD

  • TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)Drug

    1 pill of each QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the virological response to Dolutegravir/Lamivudine in pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed neonatesTime frame: From enrollment to the end of treatment at 6 months after delivery

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital General de Agudos Dr. Cosme Argerich

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Sanatorio Güemes

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Hospital de Agudos J.A. Fernandez

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Hospital Nacional Profesor Alejandro Posadas

    El Palomar, Buenos Aires, Argentina · Not yet recruiting

  • Hospital de Agudos Paroissien

    Isidro Casanova, Buenos Aires, Argentina · Not yet recruiting

  • RDSS - Ricardo Sobhie Diaz & Cia Solucoes Cientificas Ltda - Ricardo Diaz Scientific Solution

    São Paulo, Brazil · Not yet recruiting

  • Fundação Bahiana de Infectologia

    Salvador, Estado de Bahia, Brazil · Not yet recruiting

  • Complexo do Hospital de Clínicas da UFPR/Ebserh

    Curitiba, Pernambuco, Brazil · Not yet recruiting

  • Hospital Geral de Nova Iguaçu

    Nova Iguaçu, Rio de Janeiro, Brazil · Not yet recruiting

  • Universidade Federal do Rio Grande do Norte

    Natal, Rio Grande do Norte, Brazil · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.